TAYSHA GENE THERAPIES
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.
TAYSHA GENE THERAPIES
Social Links:
Industry:
Biotechnology Genetics Life Science
Founded:
2020-01-01
Address:
Dallas, Texas, United States
Country:
United States
Website Url:
http://www.tayshagtx.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
543 M USD
Technology used in webpage:
IPv6 Pound Sterling COVID-19 Akamai Hosted
Similar Organizations
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Trinity Capital
Trinity Capital investment in Post-IPO Debt - Taysha Gene Therapies
Octagon Capital Advisors
Octagon Capital Advisors investment in Post-IPO Equity - Taysha Gene Therapies
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Taysha Gene Therapies
Acuta Capital Partners
Acuta Capital Partners investment in Post-IPO Equity - Taysha Gene Therapies
RTW Investments
RTW Investments investment in Post-IPO Equity - Taysha Gene Therapies
B Capital
B Capital investment in Post-IPO Equity - Taysha Gene Therapies
GordonMD Global Investments
GordonMD Global Investments investment in Post-IPO Equity - Taysha Gene Therapies
PBM Capital Group
PBM Capital Group investment in Post-IPO Equity - Taysha Gene Therapies
Invus
Invus investment in Post-IPO Equity - Taysha Gene Therapies
Kynam Capital Management
Kynam Capital Management investment in Post-IPO Equity - Taysha Gene Therapies
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-16 | Taysha Gene Therapies Announces Executive Leadership Changes |
Official Site Inspections
http://www.tayshagtx.com Semrush global rank: 2.29 M Semrush visits lastest month: 8.64 K
Unable to get host informations!!!
More informations about "Taysha Gene Therapies"
Texas independence group says 'big tech' silencing Texit push
13 hours ago The Texas Nationalist Movement (TNM), which is campaigning for Texas to leave the United States, has claimed 80 percent of the groups email's that reference its name or …See details»
Taysha GTx
At Taysha Gene Therapies, we believe that with a steadfast focus on the targeted execution of our gene therapy programs, we can dramatically improve the lives of patients living with diseases of the central nervous system (CNS) caused by …See details»
About Us - Taysha GTx
Mar 14, 2025 Taysha Gene Therapies is singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central …See details»
Patients & Caregivers - Taysha GTx
Patients, caregivers and families of those affected by rare CNS diseases are the foundation for everything we do. We are committed to understanding the …See details»
Release Details - ir.tayshagtx.com
Across all levels of the organization, we are building a team that has the passion, experience and talent to execute on our mission of eradicating monogenic CNS disease.” ... More information …See details»
Taysha Gene Therapies - Crunchbase Company Profile …
Contact Email [email protected] Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate …See details»
Taysha Gene Therapies to Release Full-Year 2024 Financial Results …
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV) …See details»
Pipeline - Taysha GTx
Rett syndrome is a rare progressive neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in …See details»
Taysha Gene Therapies Reports Full-Year 2024 Financial Results …
Feb 26, 2025 The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing …See details»
Healthcare Professionals - Taysha GTx
Taysha is evaluating the safety and preliminary efficacy of TSHA-102 in the REVEAL Adolescent and Adult Trial in Canada and the United States, a Phase 1/2 first-in-human, open-label, randomized, dose-escalation and dose …See details»
Our Science - Taysha GTx
Our science focuses on gene therapy programs with the potential to transform care for patients with central nervous system (CNS) diseases – starting with Rett syndrome.See details»
www.tayshagtx.org
Www.tayshagtx.orgSee details»
Taysha Gene Therapies - Company Profile & Staff Directory
Taysha Gene Therapies | 9,454 followers on LinkedIn. Taysha Gene Therapies is on a mission to eradicate severe and life-threatening monogenic CNS disease. | Taysha Gene Therapies is on …See details»
Release Details - ir.tayshagtx.com
Oct 22, 2024 The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing …See details»
SEC Filing | Taysha Gene Therapies - ir.tayshagtx.com
As an organization, we are preparing to conduct our first Phase 1/2 clinical trial, and have never conducted pivotal clinical trials, and may be unable to do so for any product candidates we …See details»
Release Details - Taysha Gene Therapies
Nov 12, 2020 The company anticipates more than tripling its headcount from its IPO by the end of 2020 across all areas of the organization. Financial Results As of September 30, 2020 , …See details»
Taysha Gene Therapies - Craft
Oct 29, 2024 Taysha Gene Therapies has 4 employees at their 1 location and $8.33 m in annual revenue in FY 2024. See insights on Taysha Gene Therapies including office locations, …See details»
Taysha Gene Therapies | LinkedIn
Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central …See details»
Taysha Gene Therapies: Employee Directory | ZoomInfo.com
May 7, 2024 Taysha Gene Therapies Contact Info: Phone number: (214) 612-0000 Website: tayshagtx.com What does Taysha Gene Therapies do? Taysha Gene Therapies (Nasdaq: …See details»
Taysha Gene Therapies - Overview, News & Similar companies
Jun 6, 2024 Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene …See details»